Homepage Top Section2

The designation follows two randomised, controlled Phase III trials that showed significant pain reduction, good tolerability, and no evidence of dependence. A Phase III comparator study found VER-01

Jascayd is said to be the first phosphodiesterase 4B (PDE4B) inhibitor with antifibrotic and immunomodulatory effects to be approved for these uses. Japan is the fourth country to

The companies are also launching their first collaboratively developed product, Aridol, and plan to introduce further branded products in the future. The collaboration integrates Arna Pharma’s development expertise

With this authorisation, the UAE is said to become the first nation worldwide to approve this treatment, which is offered in 1mg and 2mg doses. This move underscores

The move leverages CTTQ’s extensive reach and portfolio in liver disease, covering more than 5,000 medical centres in China. Under this agreement, the company will manage the importation,

The upgrade focuses on providing a unified and accessible framework, eliminating redundant review steps and supporting drug discovery and development projects. With this updated licensing policy, customers have

The location will serve as Novartis’ first RLT manufacturing site in Texas and is the company’s fifth such site in the country, increasing supply chain reach for the

Waiv will use its computational pathology platform to work with early phase data, which will involve analysis of tumour microenvironments using haematoxylin and eosin (H&E), as well as

The therapy is approved by the US Food and Drug Administration (FDA) for adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) following at least one prior systemic treatment. The